Histone methyltransferase SUV420H1/KMT5B contributes to poor prognosis in hepatocellular carcinoma.

MLA

Kato, Hirotaka, et al. “Histone Methyltransferase SUV420H1/KMT5B Contributes to Poor Prognosis in Hepatocellular Carcinoma.” Cancer Science, vol. 115, no. 2, Feb. 2024, pp. 385–400. EBSCOhost, https://doi.org/10.1111/cas.16038.

APA

Kato, H., Hayami, S., Ueno, M., Suzaki, N., Nakamura, M., Yoshimura, T., Miyamoto, A., Shigekawa, Y., Okada, K.-I., Miyazawa, M., Kitahata, Y., Ehata, S., Hamamoto, R., Yamaue, H., & Kawai, M. (2024). Histone methyltransferase SUV420H1/KMT5B contributes to poor prognosis in hepatocellular carcinoma. Cancer Science, 115(2), 385–400. https://doi.org/10.1111/cas.16038

Chicago

Kato, Hirotaka, Shinya Hayami, Masaki Ueno, Norihiko Suzaki, Masashi Nakamura, Tomohiro Yoshimura, Atsushi Miyamoto, et al. 2024. “Histone Methyltransferase SUV420H1/KMT5B Contributes to Poor Prognosis in Hepatocellular Carcinoma.” Cancer Science 115 (2): 385–400. doi:10.1111/cas.16038.